BioCorRx Acquires LUCEMYRA, Expands Treatment for Opioid Withdrawal and Drives Revenue Growth
TL;DR
BioCorRx Inc. acquired LUCEMYRA® (lofexidine), the FDA-Approved Opioid Withdrawal Medication, giving them a competitive edge in the substance abuse treatment market.
LUCEMYRA® is a non-opioid medication approved by the FDA to alleviate opioid withdrawal symptoms by reducing the release of norepinephrine.
BioCorRx's acquisition of LUCEMYRA® provides critical relief for patients undergoing opioid detoxification, improving the quality of life for individuals struggling with substance abuse.
Research funded by NIH to develop BICX104, a naltrexone implant for methamphetamine use disorder, offers hope for combating the growing public health challenge of MUD.
Found this article helpful?
Share it with your network and spread the knowledge!
BioCorRx Pharmaceuticals has reported substantial business growth in the first quarter of 2025, highlighted by its strategic acquisition of LUCEMYRA®, an FDA-approved medication for mitigating opioid withdrawal symptoms. The company's net product revenues from LUCEMYRA jumped from $3,620 in the same period in 2024 to $134,899 in 2025, signaling a promising trajectory for the pharmaceutical subsidiary.
The acquisition of LUCEMYRA represents a significant advancement in addressing the ongoing opioid crisis. As the first and only non-opioid medication approved by the FDA to help manage withdrawal symptoms, the drug offers a critical intervention for patients undergoing opioid detoxification. This strategic move aligns with BioCorRx's commitment to developing innovative treatment solutions for substance use disorders.
Alongside the LUCEMYRA acquisition, the company continues developing sustained-release naltrexone products, supported by a substantial grant from the National Institutes of Health. The grant focuses on BICX104, a subcutaneous implantable pellet targeting methamphetamine use disorder (MUD), a significant public health challenge with no currently approved medications.
CEO Lourdes Felix emphasized the company's focus on managing and reducing operating expenses, which have decreased by approximately 9% compared to the same period in 2024. The company anticipates LUCEMYRA will continue to be a key revenue driver and expects to enhance shareholder value through strategic pharmaceutical developments.
With ongoing research into treatment options for substance use disorders and a demonstrated ability to generate revenue, BioCorRx is positioning itself as an innovative player in addressing complex healthcare challenges related to addiction and withdrawal.
Curated from NewMediaWire
